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THE ROLE OF LOW DOSE BUSULFAN (BU) (4MG/RG) WITH 
CYCLOPHOSPHAMIDE (CY) AS A CONDITIONING REGIMEN FOR 
SEVERE APLASTIC ANAEMIA (SAA) 
Dulley, F.L.2; Vigor#o, Aft; Aranha, F.p.1; R'aiz, M.A.S; Saboya, R.:; 
~Iacedo, ]VI.C.e; Da Silva, R.L.:; De Soltza, C.A. I 1. Booze ~[arrow 
TransplmTtatio,~, State U~ive*si U ofCmnpinas, Campinas, &zoPaulo, 
Brazil; 2. U*zive'rsity of Sao Paulo, Sao Paulo, Sao Paulo, Brazil; 
3. Faculty of MediciTze -SJRPreto, SffRPreto, Sao Paulo, B~:azil. 
Bu is an agent currently used in BMT.Bu have minor toxicity to 
the lymphoid system and cause little immnnosuppression. Howev- 
er, successful allogeneic engraftment after the Tutschka regimen 
suggests that Bu can enhance the immunosupressive properties of 
Cy. Graft rejection has been a problem in SAA who were condi- 
tioned with Cy alone.Aiming to reduce graft rejection and to 
improve the immunosuppressive activity of Cy, we used Bn/Cy 
4mg/Kg and 200mg/Kg, respectively, as a conditioning in 8I pts 
with SAA.Pts were 3-53 years of age (mean, 24). The previous 
transfusions number was 1-276 (mean, 39), and 48% had therapy 
immunossupressive before transplant. MTX/CSA were used in 
order to prevent GVHD. 12/81 (15%) pts rejected their transplants 
in a mean time of 317 days (28-1001), 2 primarily (3%) and 10 
(12%) as a late rejection, aGVHD grades 2 or 3 occurred in 20/67 
(31%) pts and cGVHD in 24/61 (39%). The actuarial survival rate 
at 2850 days was 56% (CI 46-68%). In the nnivariate analysis age, 
previous treatment, number of previous transfusions, time of CSA 
use and aGVHD were statistically significant for survival. The OS 
for patients who received less and nmre than 15 transfusions was 
78% and 50%, respectively (P=0, 001); less and more than 50 
transfusions was 67% and 28%, respectively (P=0, 002). The 
cumulative incidence of rejection was 22% (CI 10-33%). In the 
univariate analysis number of previous transfusions and time of 
CSA were statistically significant for rejection. The cumulative 
incidence of rejection for patients who received less and more than 
50 transfusions was 15% and 43%, respectively (P=0, 06). The fol- 
lowing" risk factors were statistically significant for survival in the 
multivariate analysis: number of previous transfnsions, time of 
CSA, and aGVHD; for rejection: number of previous transfusions, 
and time of CSA.Low dose Bu/Cy showed to be effective and safe 
as conditioning regimen for SAA with acceptable rejection and 
survival rates. Moreover, higher number of transfusions showed to 
be associated with poor survival and more frequent rejections. 
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QUANTITATIVE DETECTION OF CHIMERISM AFTER ALLOGENEIC 
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION 
Ding-Pil~g, C.1; I'2uo-Chie~, T.~; Po Nan, 14~; C,Sing-PiJlg, T.S; 
Chien-Feng, S. t 1. Depm'tment of Cli~ical Pathology, ChaTzg Gulzg 
Memorial Hospital, Tao-Yztan, Taipei, Taiwan; 2. Department of 
Hematology-Oncology, Cha~g G'ang Memorial Hospital, Tao-Faan, 
Taipei, Taiwan; 3. School of Medical Tech**ology, Cha,zg Grog U~ziver- 
sity, Tao-Dtan, Taipei, Taiwan. 
For peripheral blood stem cell transplantation (PSCT), several 
methods for engraftment analysis, including detection f restric- 
tion fragment length polymorphisms and amplification of poly- 
morphic genetic loci, have been described previously. We report 
here a quantitative, non-isotopic method using short tandem 
repeat (STR) marker to facilitate the monitoring of engraftment. 
The DNA from the donors and the pre-transplant recipients were 
amplified with the AmpF1STR Profiler Plus kit that contained 9
STR markers. The fluorescent polymerase chain reaction prod- 
ucts were then fractionated on the ]d01yacrylamide gels in the ABI 
PRISM 377 DNA Sequencer and were analyzed by the GeneScan 
2.1 software. The best markers were selected as the informative 
alleles to distinguish donor from recipient. For quantitative analy- 
sis of engraftment, the chimeric samples were prepared by mixing 
pretransplant recipient and donor DNAs in different ratio to gen- 
erate a standard curve. After amplifying the post-transplant recipi- 
ent DNA, the extent of engraftment was determined by interpo- 
lating the percent peak area of the informative alleles according to 
the standard curve. This method was evaluated by the samples 
from 30 patients who received allogeneic PSCT during 1999 to 
2002. Four of them were informative for some degree of mixed 
chimerism indicating leukemic relapse. Of these 4 cases, 35%, 
6.5%, 15.5%, and 2.7% recipient DNA were first detected in the 
third, tenth, fourth, and fourth month after PSCT, respectively. 
These four mixed chimeric patients were soon treated with a rapid 
taper of immunosuppression. Three of them were then allowed a 
second PBST. In summary, this method provided an accurate, 
qlmntitative, and early assessment of mixed chimerism in post- 
transplant patients. Such information may be useful to guide 
implementation f additional treatment tocircumvent graft failure 
or relapse in the future. 
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STEM CELL TRANSPLANTATION IN AUSTRALIA AND NEW ZEALAND: 
AN UPDATE FROM THE AUSTRALASIAN BONE MARROW TRANS- 
PLANT RECIPIENT REGISTRY (ABt4TRR) 
Sze'l; j.1; B¢adstock, K.2, NivisoJJ-Smitb, I.S; Dodds, A. s 1. Bolze 3elm'- 
row TransplaTzt Service, Royal MelbomT~e Hospital, ~lelbouT~ze, l,'TC, 
Am'~lvlia; 2. ~Vestmead Hospital, Sydney, NSW, Aztsc~vlia; 3. St l'%- 
ce~zt's Hospital, Sydney, NS~V, Azlstralia. 
The ABMTRR has captured ata for an estimated 99.5% of trans- 
plants performed in the region from 1992-2001. In 2001, 1042 
transplants were performed, fewer than the peak of 1094 in 1998. 
This change is due to a reduction in staged, autologous transplants 
(mainly for breast cancer) and allografts for CML, despite an 
increase in unrelated onor and reduced-intensity allografts. For 
adult patients, the most common indications for single autografts 
(total 578) were NHL (42%), myeloma (35%) and Hodgldn lym- 
phorna (9%). There were 17 transplants performed for solid 
tumours (3 %) and 4 for autoinmmne disease, while 34 staged auto- 
grafts were done for myeloma (6), germ cell tammurs (6), breast can- 
cer (4) and others (18). Of 232 related onor allografts, AML (31%), 
CML (16%), ALL (11%) and NHL (10%) were the most conmaon 
indications. In i996, 97 patients were transplanted for breast cancer 
while in 2001 there were only 6. In 1999, there were 81 allografts 
for CML, 73 in 2000, but only 38 in 2001 coinciding with the initia- 
tion of trials with imafinih mesylate. For CML in Ist chronic phase, 
the numbers dropped from 63 in 1999 to 29 in 200I. Outcome data 
were available with a minimmn of 12 nmnths follow-up. For allo- 
grafts, the major cause of death in the first and second year was 
relapse (26%, 68%) with GVHD responsible for 15% and 5% 
respectively. For antografts disease-related deaths were 78% and 
86% in the first and second years. Of I673 adult recipients of related 
donor allografts, the estimated probability of survival at 9 years was 
42% and was 32% for 406 VUDS. We conclude that the ABMTRR 
is a valuable resource in identifying trends in transplantation. 
~ 2001 Australia 2001 New Zealand 
Total u ansplants ] 937 105 
Male;Female 582:355 61:44 
%male 02.1 58.1 
Number ol autografts 611 67 
AIIo related 234 29 
92 9 Allo unrelated 
ist tran~plant~ (allo&auto) 871 104 
2nd or 3rd transplants 66 l 
~taged autograt~s 57 3 
mismatched al/ografts 24 4 
age range tyr/ .3 75 1 64 
Aged 0-15 yr 109 22 
Aged 16-49 yr 391 45 
Aged 50+ yr 437 38 
% aged 50+ yz 46 6 362 
Number of contfibt,ting centres 3I 6 
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EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION ON BONE 
MARROW (BM) ANGIOGENESIS IN CHRONIC MYELOGENOUS LEUKEMIA 
Kumar, S.; Litzow, M.R.; R_ajkumar, S. 3/layo Cli~zic, Rochester, MN. 
Aim: Angiogenesis or new vessel formation is integral to the 
biology of many malignancies. Increased BM angiogenesis has 
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been demonstrated in patients with chronic myelogenous 
leukemia (CML). Allogeneic stem cell transplantation (ASCT) can 
be curative for patients (pts) with CML. It is not known if the 
abnormal BM angiogenesis changes following SCT. We studied 
the effect of SCT on BM microvesseI density (MVD) in CML and 
examined the prognostic value of pre and post ransplant (Tx) 
MVD. Patients and Methods: We evaluated MVD from BM 
samples obtained just prior to and at 3-5 months after ASCT in 
38 CML pts.31 pts each had either pre-Tx or post-Tx biopsies 
and 24 pts had both pre and post Tx biopsies available for com- 
parison. Microvessels were stained using immunohistochemical 
staining for vonWillebrand factor, using a labeled streptavidin- 
biotin peroxidase method. MVD was estimated by determining 
the average number of vessels in 3 hot spots examined at 400x 
magnification. The angiogenesis was graded as low (MVD < 10), 
intermediate (MVD < 20) or high (MVD >= 20). Results: The 
median MVD pre Tx for 31 pts was 14 (4-37); with 13 pts having 
high-grade angiogenesis, 12 intermediate-grade and 6 low-grade. 
The median post Tx MVD in 31 pts was 20 (range 5-36) with 16 
pts having high-grade angiogenesis, 13 intermediate-grade and 2 
low-grade. The median time between biopsies was 4 months 
(range 1-6 months). There was no significant change in the fol- 
lowing Tx (P =0.8, paired t-test). The MVD increased in 12 pts 
(median increase 8), decreased in 10 (median decrease 9) and 
remained unchanged in 2. The pre or post Tx MVD did not pre- 
dict relapse free or overall survival following SCT. The microves- 
sels in the post Tx BM demonstrated striking dilatation compared 
to the pre-Tx marrow. Conclusion: BM angiogenesis seen in 
CML does not change significantly following allogeneic SCT. 
These results are consistent with what we have observed in 
patients with nmltiple myeloma receiving high dose or conven- 
tional therapy and also with other reports. It is possible that per- 
sistent vessels may serve as a nidus for tumor relapse, however we 
were not able to demonstrate such an effect in our small group. 
This data provide further evidence against using regression of 
angiogenesis a a marker of therapeutic response, even in the con- 
text of anti-angiogenic therapy. 
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INFECTIONS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION 
(ALLO-BMT) IN SOUTH BRAZIL: LOW INCIDENCE OF INVASIVE FUN- 
GAL INFECTIONS DESPITE LOW-DOSE FLUCONAZOLE PROPHYLAXIS 
Bitte~Tcourt, H.; Segato, A.; Paz, A.; Sa~tos, 3/1.; Fischer, G.; Catelli, 
D.; BittelTcou~'t, R.; Fogliatto, L.; Fe~amtes, F.; Daudt, L.; Astigarra- 
ga, C.; F*'iedeHsch, J.; O,mere T.; Silla, L. Hospital de Cli*zicas de 
Po*'to Alegre, Porto Alegre, B*:azil. 
infections remains amain cause of morbidity and mortality after 
allo-BMT. Herein we describe our data concerning infections 
incidence until D+100 after BMT. We retrospectively reviewed 
98 patients transplanted from i2/94 to 04/02 with an HLA-identi- 
cal (n-96), 1-HLA allele mismatch (n=l) or singeneic (n=l) sibling 
donor. Graft source was bone marrow in 88 patients. Median fol- 
low-up was 3 years. Median age was 31 years. Seventy-six patients 
had malignancies (CML 45, ALL/AML 27, MDS 4). Eight-eight 
patients were CMV positive. GV}tD prophylaxis was cyclosporine 
+ methotrexate in 94 patients. Uni- and multivariate analysis were 
performed with Kaplan-Meier/log rank and Cox models respec- 
tively. Transplant-related mortality (TRM) and overall survival 
(OS) were 24% (100 days) and 54% (5 years). Acute grade 2-4 
GVt-ID incidence was 32%. Fifty-four patients presented at least 
one episode of a severe bacterial infection (septicemia, septic 
shock, and pneumonia), with a cumulative incidence of 56% until 
D+100. Most frequent bacteria isolated were Staphylococcus sp. 
(n=53), E. coli (n=7) and Klebsiella sp. (n=6). In univariate analy- 
sis, no variable influencing incidence of bacterial infections, how- 
ever, there was a tendency of less bacterial infections with a higher 
nucleated cell dose graft (p=0.11). Thirty-five patients presented 
at least one episode of CMV reactivation with a cmnulative inci- 
dence of 36%. Six patients presented a CMV disease. In multivari- 
ate analysis, presence of acute GVHD grade 2-4 (HR=2.8; CI95: 
1.43-5.46; P=0.003) and recipient age more than 18 years 
(HR=0.09; CI95: 0.01-0.64; P=0.02) were associated with a higher 
incidence of CMV infection/disease. Only three patients present- 
ed a proven or probable invasive fungal infection: 1 candidemia, 1 
Aspergillus p. infection and 1 Fusarium sp. infection until D+100. 
The incidence of bacterial and CMV infections were comparable 
to the literature. On the other hand, despite use of a relatively 
lower dose of fluconazole, incidence of fungal infection was signif- 
icanty lower than expected. In our experience, use of low-dose flu- 
conazole (200mg/d) is sufficient o provide adequate prophylaxis 
for fungal infections, decreasing BMT costs. Low incidence of 
mold infections might be explained by factors other than flucona- 
zole use. 
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DNA BASED HIGH RESOLUTION TYPING : OPTIMIZED PRESELECTION 
FOR CONFIRMATORY TYPING (CT) 
~'Vittrock, J.; Rehm, P.; Rutt, C.; Baier, D.3/I. DKMS Deutsche 
K~ochel~l~mvkspet~derdatei, T~leb J~gel~, Bade*~ l,Vi#'tte~71berg, Ge*w~a~zy. 
Search speed and monetary resources can be minimized by 
inserting a DNA based high resolution typing before r questing 
an unrelated stem ceil donor for confirmatory t ping. Therefore 
the DICMS offers the possibility to request high resolution typing 
class I and II since 1992 (at least on four digits leveI). These typ- 
ings are performed with new drawn blood samples and not with 
"stored samples", because we think that donors hould be aware of 
the importance to become apotential stem cell donor soon. With 
the introduction of optimized software and changing the workfiow 
in 2000, the turnaround time from donor contact o the transmis- 
sion of the typing results could be halved from over 20 to about 
10-13 days. The results of the high resolution typings give a very 
precise preselection of donors for an allogenic stem ceil transplan- 
tation. So the donor selected for confirmatory typing after a 
request for high resolution typing is more propable to be the suit- 
able donor. We observe asteadily increasing number of high reso- 
lution typing requests that over-strides the increasing number of 
the confirmatory t pings. High resolution typings and the return- 
ing of the confirmatory typing results by the search centers 
heighten the quality of our donor data base, reduce the workload 
for the search centers and accelerate donor searches in the future. 
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CASE REPORT OF A PATIENT WITH ADULT T-CELL LEUKEMIA/LYM- 
PHOMA (ATLL) 18 MONTHS AFTER ALLOGENEIC MATCHED RELATED 
DONOR PERIPHERAL STEM CELL TRANSPLANT 
Stola1-, K.; Uaugha1~, H,~.; Salzma~, D.; Lopez, R.; Gavcia, ,4. Boise 
Marrow Tr.allsphmt, Universi O, of Alabama at Bi~wJi*Nha'm, Bi~w~ing- 
ham, AL. 
The long term prognosis for persons affected with Adult t-cell 
leukemia/lymphoma associated with HTLV -1 disease is dismal. 
We report a case in which a patient is without evidence of disease 
at 18 months after peripheral blood stem ceil transplant. Her 
brother was her matched onor. She was treated with Fludarabine 
and Busulfex conditioning regimen prior to transplant. She is thiry 
nine years old, African American, diagnosed in November 2000. 
She presented with palpable adenopathy, hepatomegaly, elevated 
WBC of forty-four thousand and eight nine percent lymphocytes, 
hypercalcemia, elevated LDH, pleural effilsion, pericardial effu- 
sion and multiple areas of adenopathy in her chest. HTLV 1 anti- 
body was reactive. Bone marrow biopsy and thoracentesis were 
both consistent with ATLL. Complex chromosome abnormalities 
were present including trisomy 3 and 7. She received 2 cycles of 
adriamycin, VP-16, dexamethasone with decrease in adenopathy 
and was brought o transplant after passing the requisite pretrans- 
plant organ testing. She received 16 doses of high dose Busulfex 
per pharmacokinetic dosing every six hours, Fludarabine at 
40mg/m2, one dose daily for 5 consecutive days, and antithymo- 
cyte globulin 15mg/kg for four doses. Her graft versus host dis- 
ease prevention included long course methotrexate and 
cyclosporine. Evaluations at 100 days, 200 days, 1 year and 18 
months show no radiographic evidence of disease. FISH studies 
consistently show 100% male donor chromosomes. Bone marrow 
aspirate and biopsy at one year shows normal tissue morphology 
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